Financials data is unavailable for this security.
View more
Year on year Astec Lifesciences Ltd 's revenues fell -27.06% from 6.28bn to 4.58bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 255.65m to a loss of 469.30m.
| Gross margin | 22.47% |
|---|---|
| Net profit margin | -20.38% |
| Operating margin | -23.74% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Astec Lifesciences Ltd did not generate a significant amount of cash. Cash Flow from Financing totalled 1.48bn or 32.34% of revenues. In addition the company generated 102.21m in cash from operations while cash used for investing totalled 1.35bn.
| Cash flow per share | -21.57 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items dropped -283.56%.
| Div yield(5 year avg) | 0.14% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -1,413.51 |
More ▼
